Current Drug Targets

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556


Targeting: The ADEPT Story So Far

Author(s): K. D. Bagshawe.


Antibody-directed enzyme prodrug therapy aims to restrict the action of a cytotoxic drug to cancer sites. An enzyme that has no human analogue is delivered to cancer sites by attachment to an antibody directed at a tumour associated antigen. In a second step an antibody or other agent inactivates and clears enzyme from blood. The third step is administration of a low toxicity prodrug that is a substrate for the enzyme thus generating a potent cytotoxic agent at cancer sites. Encouraging results were obtained with this system in small scale clinical trials using unrefined agents. During the past 10 years attempts have been made to reduce the system to two components. Although these have met with some success it is now accepted that future progress requires all three components.

Keywords: ADEPT, antibody, enzyme, prodrug, fusion proteins, cancer therapy

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2009
Page: [152 - 157]
Pages: 6
DOI: 10.2174/138945009787354520
Price: $58